Multiple Myeloma Trials

Janssen 54767414MMY3008

A phase 3 study comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs. Lenalidomide and Dexamethasone (Rd) in subjects with previously untreated Multiple Myeloma who are Ineligible for High Dose Therapy

Amgen 20090482 (AMG 162)

A randomized, double-blind, multicenter study of Denosumab compared with Zoledronic Acid (Zometa) in the treatment of Bone Disease in subjects with newly diagnosed Multiple Myeloma

For More Information Please Contact

Tom Voulgaris
Director, Research Department

2240 W Woolbright Road
Suite 415
Boynton Beach, FL 33426

561-737-6556 (Office)
561-737-9244 (Fax)

Ranger Computer